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Abstract
Background Varicose veins are common and can impact
patients’ quality of life, but consensus regarding the eval-
uation of varicose vein symptoms is lacking and existing
measures have limitations.
Objective This research aimed to develop and establish the
content validity of a new electronic patient-reported out-
come (PRO) measure, the VVSymQ instrument, to assess
symptoms of superficial venous insufficiency (varicose
veins) in clinical trials.
Methods The development of the VVSymQ instrument
began with qualitative interviews with patients based on
the symptom domain of the VEINES-QOL/Sym, an exist-
ing PRO instrument for chronic venous disorders of the leg.
Three phases of qualitative research were conducted to
examine the relevance and importance of the symptoms to
patients with varicose veins, and the patients’ ability to
understand and use the VVSymQ instrument. The
development included evaluating questions that had
1-week and 24-h recall periods, and paper and electronic
versions of the new instrument.
Results Five symptoms (heaviness, achiness, swelling,
throbbing, and itching [HASTITM]) were consistently
reported by patients across all sources of qualitative data.
The final version of the VVSymQ instrument queries
patients on the HASTITM symptoms using a 24-h recall
period and a 6-point duration-based response scale ranging
from ‘‘None of the time’’ to ‘‘All of the time,’’ and is
administered daily via an electronic diary. Cognitive
interviews demonstrated varicose vein patients’ under-
standing of and their ability to use the final version of the
VVSymQ instrument.
Conclusion Content validity was established for the
VVSymQ instrument, which assesses the five HASTITM
symptoms of varicose veins daily via an electronic diary
and has promise for use in research and practice.
Key Points for Decision Makers
Existing instruments for the evaluation of varicose
veins have limitations pertaining to symptom
assessment from the patient perspective.
Symptoms that patients deem most important were
identified, i.e., heaviness, achiness, swelling,
throbbing, and itching (HASTITM symptoms).
A new patient-reported outcome daily diary
instrument, the VVSymQ instrument, was
developed, and its content validity was established. It
can be used to capture the patient experience of
HASTITM symptoms related to superficial venous
insufficiency (varicose veins) in clinical trials using a
6-point duration-based scale.
1 Introduction
Varicose veins affect up to 73 % of women and up to
56 % of men [1]. Varicose veins in the lower extremities
can be associated with heavy, aching, and restless legs,
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swelling and night cramps, and burning and tingling
sensations [2, 3]. In the early stages, varicose veins may
present a variably painful problem; progression typically
leads to severe and largely irreversible problems of
chronic venous insufficiency (CVI). A severe and debili-
tating outcome of CVI in the lower limbs is lower
extremity ulceration [4].
To understand the effects of treatment, it is important
to evaluate the patient’s experience of symptoms and
symptom impact on functional health and well-being.
Symptoms vary among individuals, and some treatment
effects are not directly observable by clinicians, thus,
symptoms are best measured using patient-reported out-
come (PRO) measures, as recommended in the US FDA
Guidance for Industry: Patient-Reported Outcome Mea-
sures: Use in Medical Product Development to Support
Labeling Claims (FDA PRO guidance) [5]. Currently, a
lack of consensus regarding the best way to evaluate
symptoms of varicose veins and chronic venous disease is
evidenced by the wide range of measures used in previous
studies [3]. Available instruments (e.g., Aberdeen Vari-
cose Veins Questionnaire [AVVQ] [6], Chronic Venous
Insufficiency quality of life Questionnaire [CIVIQ-20]
[7]) do not exclusively measure patient-reported symp-
toms associated with varicose veins and were not devel-
oped to meet regulatory expectations to support labeling
claims [5, 8]. Widely used measures such as the
Venous Insufficiency Epidemiological and Economic
Study instrument (VEINES-QOL/Sym), used for evaluat-
ing the broad range of chronic venous disorders of the leg
(CVDL) [3], are not specific enough or adequately
responsive to changes in symptoms reported by patients
treated for superficial venous insufficiency [9]. Addition-
ally, whereas initial draft versions of the VEINES-QOL/
Sym were pilot tested with patients, no patients, and none
with varicose veins, were involved in the initial item-
generation process [3].
To address the need for a PRO measure for assessing
symptoms of superficial venous insufficiency (varicose
veins) in clinical trials that are conducted to support
labeling claims for symptom improvement, research was
conducted to develop a new instrument that focuses
exclusively on symptoms. This research followed FDA
guidelines for measure development, including an appro-
priate recall period and patient input for the generation of
questions (FDA PRO guidance) [5]. The initial develop-
ment work for this new measure was based on the existing
VEINES-QOL/Sym [3], and three phases of qualitative
patient interview work were conducted to result in the final,
electronic version of a new measure called the VVSymQ
instrument. The current report delineates the evolution of
and the establishment of the content validity of the
VVSymQ instrument.
2 VEINES-QOL/Sym
The research to develop the VVSymQ instrument built on
previous work conducted to develop the VEINES-QOL/
Sym questionnaire [3]. The 26-item VEINES-QOL/Sym
includes two content domains: (1) QOL (VEINES-QOL)
and (2) symptoms (VEINES-Sym). The symptoms domain
consists of ten items that provided the basis for the
development of the new PRO instrument.
The generation of potential symptom items for the
VEINES-Sym domain was based on expert clinical opinion
about the problems commonly reported by patients with
CVDL and literature reviews of PROs and existing outcome
measures in CVDL [3], which supported the conclusion that
symptoms are important to patients. From these sources,
potential items were generated through consensus discus-
sions with a multidisciplinary group of clinicians and
methodologists with expertise in CVDL, questionnaire
design, psychometrics, and epidemiology. The resultant
symptoms assessed in the VEINES-Sym domain were heavy
legs, aching, swelling, night cramps, restlessness, heat or
burning sensation, throbbing, itching, tingling sensation, and
pain, and the authors based the format of the items and
4-week recall period on the Medical Outcomes Study
36-Item Short-Form Health Survey (SF-36) [10].
3 Modification of the VEINES-QOL/Sym
To begin the development of the new PRO instrument that
met FDA standards, the VEINES-QOL/Sym was first
adapted by shortening the recall period to 1 week and by
changing the response options to a 6-point scale ranging
from ‘‘None of the Time’’ to ‘‘All of the Time’’ to reflect
this shorter recall period. The modified (m)-VEINES-QOL/
Sym instrument, administered on paper, provided the
starting point for new qualitative research with patients.
Study protocols were Institutional Review Board
approved, and patients provided written informed consent.
In all studies, investigators identified potential patients
from their existing medical records; patients were recruited
by letter or email (or from a waiting room flyer or
newsletter posting), and screened for study eligibility either
in person or via telephone by clinic staff.
4 Qualitative Patient Interviews: Phase 1
(Modified VEINES-QOL/Sym)
4.1 Phase 1 Methods
Initial qualitative research in 2008 was conducted via three
concept-elicitation focus groups and individual cognitive
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interviews with additional patients who were recruited
from two clinical sites in Fort Myers, Florida, and Panama
City, Florida, USA. The following objectives were inclu-
ded: obtain open-ended input from patients regarding their
symptoms, evaluate patients’ ability to understand and use
the symptom domain of the m-VEINES-QOL/Sym, eval-
uate the 1-week recall period and 6-point duration-based
scale, and ensure that all relevant symptoms of varicose
veins were captured.
Patients were eligible for the study if they were aged
18–60 years, had been either evaluated or treated for severe
varicose veins within the previous 6 months, and had a
physician’s diagnosis of saphenous vein incompetence,
severe varicose veins, and a Clinical, Etiology, Anatomy,
Pathophysiology (CEAP classification for lower extremity
disorders) of 3 (edema), 4 (skin changes without ulcera-
tion), or 5 (skin changes with healed ulceration). Patients in
this phase of study were not evaluated for current symp-
toms of varicose veins at screening.
The interviewers were qualitative research scientists
with extensive experience in qualitative interviewing with
patients across a broad range of therapeutic indications.
Each focus group session was a one-time group interview,
and the primary discussions centered on patients’ spon-
taneous description of their varicose vein symptoms.
Following the open-ended discussion, patients completed
the modified (m)-VEINES-QOL/Sym, and took part in a
group debriefing session to explore patients’ understand-
ing of symptom items and probe specifically on the
acceptability of the 6-point scale and one-week recall
period.
For the individual cognitive debriefing interviews, a
separate set of patients completed the m-VEINES-QOL/
Sym. Using a semi-structured discussion guide, inter-
viewers explored the m-VEINES-QOL/Sym items with
respect to relevance, understanding, and acceptance of the
modified recall period and response scale.
Sessions were audio-recorded and data were transcribed.
Descriptive statistics were used to characterize the samples
in terms of sociodemographic and clinical characteristics.
To evaluate the qualitative data, ATLAS.ti qualitative
analysis software [11] was used to assist with content
analysis, and in-depth review of transcripts was performed
with transcription of key points, which served as the pri-
mary data source for the analyses. Saturation of concept
analysis was conducted as assessment of the focus group
data quality.
Saturation of concept is defined as the point at which no
new relevant information is likely to be gained from con-
ducting additional research (e.g., focus group sessions or
interviews) [5]. In this research, saturation of concept was
evidenced by no new concepts appearing in the last tran-
script group.
4.2 Phase 1 Results
Three concept-elicitation focus groups (five to eight
patients each) were conducted with a total of 20 patients,
and individual cognitive interviews were conducted with
an additional 11 patients. See Table 1 for demographic and
clinical characteristics.
4.2.1 Phase 1 Concept-Elicitation Focus Group Results
The key results of the focus groups were the patients’
reports of symptoms relevant to their experience of vari-
cose veins. The open-ended discussions elicited a com-
prehensive list of symptoms experienced by the patients,
and all of the symptoms listed in the m-VEINES-Sym were
discussed by many of the focus group patients, although
‘itching’ was reported by only one. Table 2 shows the
number of patients who reported having experienced each
symptom and sample patient quotes illustrating the rele-
vance of these symptoms to the patients. The only addi-
tional symptoms elicited in the focus groups were
numbness and bruising, both mentioned by only one patient
with no other endorsement. Saturation of symptom concept
was achieved in the second focus group, as no novel con-
cepts were reported in the third group.
Additional exploration during the focus groups centered
on patients’ impressions of the m-VEINES-Sym 6-point
response scale and various recall periods. The majority of
the patients interpreted the items to be asking about the
frequency with which they experienced symptoms over the
past week, and all said that they felt confident in their ability
to think back over the past week and respond accurately
about their symptoms. All patients were able to use the
6-point scale to respond to the items without issue, and 88 %
agreed that no changes should be made to the scale.
The discussions with patients with varicose veins
established that concepts covered in the m-VEINES-Sym
resonated with patients and that the language used was
understood accurately. During the open-ended discussions,
every symptom in the m-VEINES-Sym was mentioned by
at least one patient, and patients used the same words to
describe symptoms as those used in the m-VEINES-Sym.
The discussions also verified that patients could compre-
hend, preferred, and in their judgment, accurately respond
when using a 1-week recall period.
4.2.2 Phase 1 Cognitive Interview Results
The individual cognitive interviews confirmed patients’
understanding of the m-VEINES-Sym items, 1-week recall
period and 6-point response scale. Most important to the
VVSymQ instrument development work were the
patients’ reports of recognition and understanding of the
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VEINES-Sym symptom concepts. Data revealed that
although the majority of patients had heard of and under-
stood each of the symptoms, many of them reported that
they had not personally experienced some of the symp-
toms, or had experienced some symptoms in the past prior
to treatment, but not recently. Further, patients offered no
other symptoms (i.e., symptoms not listed in the VEINES-
Sym) in relation to their varicose vein experience. Table 2
shows the number of patients who reported knowing of or
having experienced each symptom and sample patient
quotes.
4.2.3 Phase 1 Summary
Overall, the results of the phase 1 work confirmed accep-
tance of the 6-point response scale and the suitability of the
1-week recall period of the m-VEINES-Sym. Further, the
symptoms listed in the m-VEINES-Sym covered the
breadth of symptoms among the patients of both studies,
with only two patients in the focus groups both reporting
one symptom that was not contained in the measure.
While all of the symptoms were known to most of the
patients, some were not known to many, and other symp-
toms had not been experienced recently since beginning
treatment. Therefore, it was decided to conduct subsequent
research with patients confirmed to be experiencing
symptoms at screening.
5 Qualitative Patient Interviews:
Phase 2 (m-VEINES-Sym)
5.1 Phase 2 Methods
In 2009, three concept-elicitation focus groups and indi-
vidual cognitive debriefing interviews (novel patients)
were conducted with patients who had varicose veins and
were symptomatic. The objective was to evaluate whether
Table 1 Sociodemographic characteristics of phase 1 focus group












Female 19 (95) 11 (100)
Employment
Full-time 13 (65) 6 (54.55)
Part-time 3 (15) 0 (0)
Homemaker 1 (5) 3 (27.27)
Student 0 (0) 1 (9.09)
Disabled 0 (0) 1 (9.09)
Retired 3 (15) 0 (0)
Other 0 (0) 1 (9.09)
Education
GED/high school equivalent 1 (5) 0 (0)
High school 2 (10) 1 (9.09)
Some college 6 (30) 3 (27.27)
Graduated 2-year college 3 (15) 1 (9.09)
College 7 (35) 2 (18.18)
Completed post-graduate
degree
1 (5) 2 (18.18)
Vocational training 0 (0) 2 (18.18)
Race
Black or African American 1 (5) 0 (0)
White 19 (95) 11 (100)
Living situation
Living alone 5 (25) 0 (0)
Living with spouse, partner,
family, or friends
15 (75) 11 (100)
Marital status
Married 13 (65) 7 (63.64)
Divorced 5 (25) 1 (9.09)
Widowed 0 (0) 1 (9.09)
Never married 2 (10) 2 (18.18)
Health conditions
Arthritis 3 (15) 0 (0)
Stroke 1 (5) 0 (0)
Hypertension 3 (15) 0 (0)
Peripheral vascular disease 3 (15) 0 (0)
Diabetes 1 (5) 0 (0)
Other 2 (10) 1 (9.09)
CEAP class
CEAP class 3 = edema 10 (50) 8 (72.73)
CEAP class 4 = skin changes
due to venous disease
9 (45) 3 (27.27)
CEAP class 5 = skin changes
with healed ulceration
1 (5) 0 (0)
Treatment in the past 6 months







Sclerotherapy 7 (35) 2 (18.18)
Laser therapy 6 (30) 9 (81.82)
Radio frequency ablation 1 (5) 2 (18.18)
Other (compression
stockings)
2 (10) 0 (0)
No treatment 10 (50) 0 (0)
Data are presented as n (%) or mean ± standard deviation
CEAP clinical, etiology, anatomy, pathophysiology, GED General
Educational Development
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Table 2 Example phase 1 patient quotes demonstrating relevance of VEINES-Sym concepts
Symptom Concept-elicitation focus group (N = 20) Individual cognitive interviews (N = 11)
Heavy legs (n = 14; 70 %)
And they, and some days I, I’m just so, my feet just feel so
heavy. My legs have this heavy, heavy feeling until I just
want to sit down all day.
(n = 10; 91 %)
My legs actually feel like there’s weights on ‘em like they’re
heavy.
Well, meanwhile, the leg starts getting heavier and heavier
and heavier.
You have trouble lifting or you just feel weighted down.
Aching legs (n = 5; 25 %) (n = 10; 91 %)
It is a burning pain that aches, an achy pain. They, they hurt. You know I mean it’s just aching. It’s not
throbbing; it’s not unbearable. It’s that you’re aware of that
pain, there’s an achiness.
… it varied in intensity and typically just umm-mmm a dull
ache that would come and go.
Swelling (n = 14; 70 %) (n = 9; 82 %)
And, um, I noticed my feet started to swell up around my
ankles, and, but before that I noticed this part of my leg
started swelling …
… retaining fluid; they’re bigger than normal I mean.
… I was having, um, um, swelling, uh, in my ankle and, uh,
lower leg, but basically the ankle.
I still get a little bit of swelling at the end of the day especially.
Night cramps (n = 8; 40 %) (n = 7; 64 %)
I kind of rolled over, and my husband woke up and said,
‘‘what are you doing?’’. I said, I’ve got cramps
[laughter], and he tried to pick me up so we could walk
them out, you know. It was, it was awful.
That’s the pain that wakes you up in the middle of the night …
Oh, my god, it’s like a Charley Horse and you wake up and it’s
like you can’t sleep and you have to walk around and, you
know, it ruins your whole night’s sleep
Heat or burning sensation (n = 12; 60 %) (n = 7; 64 %)
And I was having burning and the swelling, so I decided to
come and find out.
That’s one of them that came up when on my, one on my legs.
This like here has one vein that it’s new and it came up and
umm-mmm it’s sticking out a little bit and it was burning and
has an itching and scratching it so … they’re
uncomfortable and, and they just feel warm and you just feel
like you want to itch.
For me, it’s like somebody’s turned a curling iron on inside
my leg, and it just starts to kind of emanate out. And it just
kind of keeps coming, you know, just moves up, and it hits
around the hip.
It, it I feel it’s on the bottom of my leg on, on the heel of my leg.
Once in a while I feel like uh burning.
Restless legs (n = 11; 55 %) (n = 5; 45 %)
I’ll be in bed at night and I can’t go to bed because I feel
like I just have to … I just have to stretch my legs like
that. I’m like what the hell am I doing. And, I saw on the
TV they were talking about restless leg syndrome and you
know what, there’s truth to that because I could not sleep.
I uh, uh maybe that you feel that I have to move my legs all the
time or that, that I can’t stand in one place. I have to move my
legs to make ‘em feel better.
Umm-mmm when I have it, it’s normally like when I’m sitting in
front of the TV trying to watch TV or, or at night when I’m in
bed. And it’s just like I have this uncontrollable urge to move
my feet, my legs and it’s like I try to keep ‘em still but it drives
me nuts.
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the m-VEINES-Sym item content aligned with language
used by symptomatic patients in describing their disorder,
as well as to elicit the best response options and recall
period to capture these symptoms in symptomatic patients.
An additional objective was to determine the importance of
the frequency and severity of varicose vein symptoms to
symptomatic patients. Patients were recruited from three
clinical sites in the USA (Vestavia Hills, AL; Hunt Valley,
MD; and Charlotte, NC) based on study inclusion/exclu-
sion criteria and additional clinical characteristics that were
similar to those for patients with moderate to severe vari-
cose veins who would complete a symptom instrument (the
final version of which was called the VVSymQ instru-
ment) in future clinical trials. Patients were eligible if they
were aged between 19 (the age of majority in Alabama)
and 75 years and had a current physician diagnosis of great
saphenous vein (GSV) system incompetence, specifically
demonstrating incompetence of the saphenofemoral junc-
tion (reflux[0.5 s on duplex ultrasonography) associated
with incompetence of the GSV or other major accessory
vein. Patients must have had a current diagnosis of mod-
erate to severe varicose veins and a CEAP clinical classi-
fication C2–C6 (C6 indicates active venous ulcer). Patients
had to be experiencing superficial venous disease mani-
fested by both symptoms and visible varicosities, and had
to have been evaluated or treated for the disorder within the
previous 6 months.
To ensure patients were symptomatic and had experi-
enced at least four of the nine m-VEINES-Sym symptoms
during the past week, a list of 18 symptoms was included in
the screening script. Nine of these symptoms were from the
m-VEINES-Sym; the remaining nine symptoms were
unrelated and included so as not to bias the patients to
subsequently report and discuss only the symptoms
reported during screening.
Each focus group session was a one-time group inter-
view and, as with the phase 1 work, the discussion centered
on the patients’ spontaneous description of their symptoms.
After patients had described all symptoms, the moderator
probed the group about any of the nine symptoms of the
m-VEINES-Sym that were not mentioned in the discus-
sion. Patients were also asked whether they preferred to
report each symptom in terms of frequency or severity to
confirm the appropriateness of the response scale.
For the individual cognitive debriefing interviews,
patients reviewed the nine symptoms of the m-VEINES-
Sym and were asked to identify any symptom(s) they had
not experienced as a result of their varicose veins. There-
after, patients completed the m-VEINES-QOL/Sym and
were asked a series of questions about the clarity of
instructions, recall period, and response options.
Data analyses followed the work described for phase 1.
5.2 Phase 2 Results
Three focus groups (four to eight patients each) were
conducted with 19 patients, and individual cognitive
interviews were conducted with an additional ten
Table 2 continued
Symptom Concept-elicitation focus group (N = 20) Individual cognitive interviews (N = 11)
Throbbing (n = 5; 25 %) (n = 9; 82 %)
But then as soon as you sit down and relax at the end of the
day or you lay in the bed, all of a sudden everything starts
throbbing and it’s like you don’t which way to put it, you
know.
Like the heart, pumping blood … in my calf and in my ankle.
… like a tooth ache I mean it’s just they will just like a
pounding I guess I want to say. Umm-mmm like every heart
beat I have it’s just a little pain.
Itching (n = 1; 5 %) (n = 6; 55 %)
Actually itching was having to scratch my leg ‘cause of itching.
Uh something that I just got to scratch and uh it’s an itch. I just
scratch it and it’s usually if it starts, it’s in the same, same
area. And I’ll scratch it and it’ll still burning, tingling itch.
Tingling sensation (n = 4; 20 %) (n = 4; 36 %)
There’s something tickling, very light movement across
your legs, and I asked the doctor … You start feeling
movement or things tingling in your leg.
Tingling sensation a good bit of the time. And the reason I put
that is I haven’t had it. Since I’ve had this leg done last week
and it feels like it’s actually under my calf; it feels like there’s
something crawling on my leg.
Tingling I put a little bit of the time. I’ll don’t get a lot of it but
it’s usually after the itching like if I scratch that it will tingle.
The N in each column indicates the number of patients in the concept-elicitation and cognitive interviews who reported experiencing each symptom
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patients. See Table 3 for demographic and clinical
characteristics.
5.2.1 Phase 2 Concept-Elicitation Focus Group Results
The key results of the focus groups were the patients’
reports of symptoms relevant to their experience of vari-
cose veins. The open-ended discussions elicited a com-
prehensive list of symptoms experienced by the patients
and, as with the phase 1 focus groups, all of the symptoms
listed in the m-VEINES-Sym were discussed by many of
the patients. Table 4 shows the number of patients who
reported having experienced each symptom and sample
patient quotes. Only three additional symptoms were eli-
cited in the phase 2 focus groups. Two of those, ‘‘a feeling
of ‘stuff/bugs crawling’ on the legs,’’ and ‘‘cramping dur-
ing the day (not only at night)’’ were discussed as not being
a direct result of the condition, but rather, to removal of
Table 3 Sociodemographic
characteristics of phase 2 focus
group and cognitive interview
patients
Characteristic Focus group (N = 19) Cognitive interview (N = 10)
Age, years, mean ?/-SD (range) 50.2 ± 13.6 (27–74) 46.3 ± 13.8 (29–74)
Sex
Male 5 (26.3) 1 (10.0)
Female 14 (73.7) 9 (90.0)
Ethnicity
Hispanic or Latino 0 (0.0) 1 (10.0)
Not Hispanic or Latino 19 (100.0) 9 (90.0)
Race
White 18 (94.7) 9 (90.0)
Black or African American 1 (5.3) 0
Mexican American 0 1 (10.0)
Marital status
Married 12 (63.2) 6 (60.0)
Single 1 (5.3) 2 (20.0)
Divorced/separated 5 (26.3) 1 (10.0)
Widowed 1 (5.3) 1 (10.0)
Current domestic/living situation
Living alone 4 (21.1) 2 (20.0)
Living with spouse, partner, family, or friends 15 (79.0) 8 (80.0)
Employment statusa
Full-time 11 (57.9) 5 (50.0)
Part-time 4 (21.1) 2 (20.0)
Homemaker 3 (15.8) 2 (20.0)
Retired 5 (26.3) 1 (10.0)
Education
Secondary/high school 6 (31.6) 1 (10.0)
Some college education 2 (10.5) 2 (20.0)
Graduated 2-year college 1 (5.3) 3 (30.0)
Completed college degree 2 (10.5) 2 (20.0)
Some post-graduate education 3 (15.8) 1 (10.0)
Completed post-graduate degree 4 (21.1) 1 (10.0)
Technical or vocational degree 1 (5.3) 1 (10.0)
Comorbidities
Arthritis 3 (15.8) 2 (20.0)
Hypertension 4 (21.1) 0
Peripheral vascular disease 1 (5.3) 0
Otherb 3 (15.8) 0
Data are presented as n (%) or mean ± standard deviation
a Patients could select more than one response
b ‘‘Other’’ included blood clots, hypotension, and narcolepsy
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Table 4 Example phase 2 patient quotes demonstrating relevance of VEINES-Sym concepts
Symptom Concept-elicitation focus group (N = 19) Individual cognitive interviews (N = 10)
Heavy legs (n = 19; 100 %)
The left leg does feel heavier, you know, like I’m dragging a
log.
(n = 10; 100 %)
Um, yeah literally like it weighs more than the other leg. Like it’s
dragging a little bit more than the other leg would drag.
It’s like somebody put cinder blocks on your feet or something. It feels like your legs weigh more than they actually do. They
feel, um, like they have—if you’ve ever exercised with weights
strapped around your ankles, that’s how they feel.
Aching
legs
(n = 19; 100 %)
It’s from, um, the knee down on the leg that has the largest
veins, and it’s and it doesn’t—it’s not site specific. It’s just a
dull ache in that calf area from the knee-from the knee down
to the bottom of the calf.
(n = 10; 100 %)
… it is just a constant dull ache I guess that I can feel.—I can
feel it all the time.
… that bother me the most are the achiness that I feel, um,
even after I wake up, like the next day. Um, I feel like I was
just running all night.
Umm-mmm you know—nothing I wouldn’t say you know
something so excruciating that I can stand it, but definitely
unpleasant.
Swelling (n = 18; 95 %)
It’s almost like as soon as you stand up, the weight—your body
weight starts a chain reaction to your legs almost. When they
fill up, they start swelling.
(n = 8; 80 %)
Umm-mmm just my feet look like umm-mmm little pig feet
[Laughter]. They’re just—they’re all swollen up. And you
know I uh you know a lot of times I can’t fit in a shoe or umm-
mmm you know.
Your feet swell up so bad from like, at least mine do, from my
feet maybe to a couple inches above my ankles, and they’re
just—you just can’t put shoes on. You can’t wear sandals,
because it hurts so bad because your foot is another size.
Swelling is like somebody has injected a quart of water into your
leg. It feels heavy. It feels, um, uncomfortable. It feels, um,
makes your shoes hurt.
Night
cramps
(n = 16; 84 %)
Well, the cramping, to me, is a constant, whereas the throbbing
is just periodic, like a throb, off and on. But the cramping is a
constant pain when you’re having one.
(n = 8; 60 %)
[It] wakes you up in the middle of the night, um, with your
muscles completely constricted, and you have to grab your leg,
your calf, your thigh, whichever happens to have it in there,
and try to rub it out or get up, if it’s down in your foot, and
walk it out.
… it’s like you’re all of a sudden you’ll just feel it twinging and
then it tighten, tighten, tighten. You know, you just feel like a
little twinge and then all of a sudden it escalates to-like I have
to get out of bed and stand on it to get it to alleviate or to, you




(n = 15; 79 %)
My feet and my legs just burn. I mean, it’s just—I have to go
find something, like go out in the kitchen on the linoleum or
something, because it’s cooler, trying to cool them down.
(n = 8; 80 %)
I think I can actually feel the heat of—I can actually feel warmth
around it
It’s like a hot arrow going down my legs.
Mine is the—the temperature of my skin, the hot. Like when I
go to bed at night it’s so—my legs are so hot, and there again
mine’s from the knees down where it’s the worst. But they’re
so hot that it even basically hurts for a sheet, just the bare
sheet to hurt them, because they’re so hot it feels like it
almost hurts.




(n = 15; 79 %)
… you’re—it’s almost like you’re tight and you don’t stretch
them out enough and like you’ve, um, kind of isn’t enough—I
find that if I stretch them it feels better.
(n = 5; 50 %)
Well I don’t—it’s more of those times where I’m trying to relax
them and fall asleep and then you know my legs are not relaxed
…
… you’ll wake up, and the—the lower part of the leg will be—
feels like there’s springs in your leg.
… well it keeps me from getting sleep again. Umm-mmm and it’s
just I—you can’t comfortable. It’s like you—you just you can’t
find a comfortable place to lie. You have to keep moving
around. And uh it’s very annoying.
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compression stockings and diet and activity, respectively.
The third novel symptom was the feeling of blood or fluid
rushing into the legs upon standing, which was mentioned
in only one focus group and was associated with swelling
as the main symptom. Saturation of symptom concept was
achieved in the second focus group, as no novel concepts
were reported in the third group. When asked specifically
about the 1-week recall period in the m-VEINES-Sym,
patients in all focus groups reported that they were able to
answer questions about their varicose veins symptoms
when thinking about the past week. Focus group patients
understood and were able to use the 6-point response scale
to respond to each of the nine VEINES-Sym items. Finally,
almost all patients in each focus group reported thinking of
symptoms in terms of both frequency and severity. How-
ever, when asked, patients generally preferred reporting
symptoms based on frequency, noting that it was more
informative and applicable to their symptoms.
5.2.2 Phase 2 Cognitive Interview Results
The individual cognitive interviews confirmed patients’
understanding and comprehension of the m-VEINES-Sym
items, 1-week recall period, and 6-point response scale.
Most important to the development of the future
VVSymQ instrument were the patients’ reports of
recognition and understanding of the m-VEINES-Sym
symptom concepts. While the majority of patients indi-
cated having experienced most of the symptoms in the
m-VEINES-Sym, tingling and restless legs were experi-
enced by far fewer. Table 4 shows the number of patients
who reported having experienced each symptom and
sample patient quotes.
5.2.3 Phase 2 Summary
Overall, the results of the phase 2 work confirmed accep-
tance and usability of the 6-point response scale, including
the assessment of symptoms based on frequency, as well as
the suitability of the 1-week recall period. Further, the
symptoms listed in the m-VEINES-Sym cover the breadth
of symptoms among the patients who confirmed experi-
encing symptoms of varicose veins at the time of
screening.
Across all sources in the phase 2 data, five symptoms
were consistently part of the patient experience of varicose
veins: heavy legs, aching legs, swelling, throbbing, and
itching (HASTITM symptoms). Moreover, after exclusion
of data from one cognitive debriefing patient who con-
firmed only three symptoms during the interview despite
having met all screening criteria, 89–100 % of the cogni-
tive debriefing patients identified the five symptoms as
relevant to their experiences with varicose veins. This level
of endorsement (89 %) was also seen with night cramps,
but it was excluded from the next version of the instrument
because it was not spontaneously offered in one of the
focus groups and, even with probing, was not a key
symptom emphasized in any focus group discussions. No
other symptoms related to varicose veins were discussed
extensively in the focus groups or cognitive debriefing
interviews. Almost all focus group patients reported
thinking of symptoms in terms of both frequency and
Table 4 continued
Symptom Concept-elicitation focus group (N = 19) Individual cognitive interviews (N = 10)
Throbbing (n = 18; 95 %)
Just it throbs all the way up to my groin.
(n = 9; 90 %)
Umm-mmm you just feel the—the blood almost pulsating in
there.
Yeah. If you’re on your feet a lot like I am, um, by the end of
the day, especially in the lower part of the leg, it’s just a
constant throb
… it’s just like the—like the vein itself is umm-mmm beating I
guess you would say. Almost like a heart.
Itching (n = 13; 68 %)
And it—and it itches like crazy when you first get it. Then the
itching will go away, and then it’s just a nuisance. And it’s-
it’s about like getting red bug bites is what’s it’s about like.
(n = 8; 80 %)
It’s almost like a bug bite type itch. I mean it’s just uh, a really
itchy itch.
… it’s that hot, itchy kind of bugs under the skin kind of
feeling, and, to me, that’s painful, obviously.
Um, well like the—the itching is with any kind of itching. It’s—
it’s, um, like kind of like a mosquito bite over a larger area.
Tingling
sensation
(n = 14; 74 %)
… my legs felt like they would like tingle from my toes up to
like my mid-calf to my knees.
(n = 6; 60 %)
It’s like pins are poking your—the bottom of your feet or poking
your leg …
I wake up at one in the morning with the cramps or the
soreness and the tingling in the leg.
Um, feels like when—if something like your foot or whatever
goes to sleep and it’s coming back awake.
The N in each column indicates the number of patients in the concept-elicitation and cognitive interviews who reported experiencing each
symptom
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severity, but they considered frequency of symptoms more
informative and crucial to assessing their symptom
experiences.
5.2.4 Emergence of a New Instrument
These activities resulted in a new instrument, administered
on paper, with the HASTITM symptoms as the five items
queried (Fig. 1), a 6-point response scale ranging from
‘‘None of the time’’ to ‘‘All of the time,’’ and a 7-day recall
period. This paper instrument was successfully imple-
mented in a study of the treatment of patients with varicose
veins [12]. Although the paper-based version of the new
five-item instrument with the 7-day recall period was well
received by patients with varicose veins [12], it was later
acknowledged as having potential shortcomings, including
cumbersome paper implementation (and possibly lowered
compliance rates), lack of verification of timing of
assessments, potentially inaccurate patient recall of symp-
toms over the past 7 days, and the potential for data entry
transcription errors, all of which could negatively impact
data quality.
Thus, paper was replaced with an electronic diary, the
recall period was shortened to 24 h, and this new measure
querying the five HASTITM symptoms was named the
VVSymQ instrument. To better match the descriptor in
the electronic version of questions, ‘‘heavy legs’’ and
‘‘aching legs’’ were changed to ‘‘heaviness’’ and ‘‘achi-
ness,’’ respectively. The new measure was imbedded in a
longer electronic daily diary that was implemented on a
personal digital assistant (PDA). The electronic system
included a user-friendly screen (Fig. 2) and an alarm
schedule that prompted the user to complete the assessment
at scheduled times, per protocol, and facilitated automatic
data transfers each night when the PDA was attached to the
charger, as well as back-up data transfers at clinical sites
that may be required per protocol.
6 Qualitative Patient Interviews: Phase 3
(VVSymQ Instrument in a Daily Diary)
A qualitative study was undertaken to evaluate the
VVSymQ instrument in patients with characteristics
similar to those who would use the instrument in future
clinical trials for superficial venous incompetence.
6.1 Phase 3 Methods
Cognitive debriefing interviews were conducted in four
waves with patients recruited from five clinical sites in the
USA (Vestavia Hills, AL; Hunt Valley, MD; Charlotte,
NC; Bellevue, WA; and Seattle, WA). Key recruitment
criteria were similar to those described for the phase 2
focus groups and cognitive interviews, with the exception
that the current patients were required to have at least three
of the five HASTITM symptoms in the week prior to
screening, and a CEAP clinical classification of C2–C5.
Data-driven modifications were made to the items between
waves, as necessary.
Patients were asked to complete the electronic daily
diary containing the VVSymQ instrument, and were then
asked a series of questions about the instructions, item
stem, and response options. Patients were asked about the
meaning and relevance of the item, the fit and adequacy of
the response scale, the language used, and lack of clarity in
terminology or sentence structure [13].
Fig. 1 Conceptual framework: the VVSymQ instrument (initial
version) as a measure of important varicose veins symptoms
Fig. 2 Screen image of the VVSymQ instrument in an electronic
diary
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Interviews were audio recorded and transcribed, and
quotations from the patients’ responses to each question
asked in the cognitive interview guide were summarized to
show patient interpretation and understanding of the
instructions and of each item and response option, and to
identify any difficulties that arose with the proper under-
standing of the content. Evaluation of these data focused on
(1) assessment of understanding of the draft items, and (2)
identification of potentially problematic terms or phrases
that prevent comprehension of the measure.
6.2 Phase 3 Results
Cognitive debriefing interviews were conducted in four
waves with 29 patients. Table 5 shows the demographics
and clinical characteristics for this sample.
The results of the phase 3 cognitive interviews indicated
that the electronic version of the VVSymQ instrument
was well accepted by the patients and that they generally
understood and could use the items and response options as
intended. However, some revisions to the recall period
were made between the first and second waves. After the
first wave of cognitive interviews with 11 patients, the
recall period was revised from ‘‘In the past 24 hours’’ to
‘‘Since waking today’’ in all items, based on patients’
reports of not experiencing some symptoms during sleep.
The recall period was further revised to ‘‘Since waking up
today’’ after wave 2 testing with eight patients, because
many patients misread ‘‘waking’’ as ‘‘walking.’’
The wave 3 and 4 cognitive interviews were each con-
ducted with five patients. Results indicated that version 3
of the electronic daily diary, which included the final five-
item VVSymQ instrument (HASTITM symptoms assessed
on a 6-point scale), was confirmed to be well understood
and suitable for use as intended by patients with GSV
system incompetence.
After psychometric validation in a quantitative study
[14], the five-item VVSymQ instrument was implemented
as part of an electronic daily diary in phase 3 clinical trials
of treatment of superficial venous incompetence of the
GSV system [15, 16].
7 Discussion
Symptoms are not observable by clinicians and can be
evaluated only by patients’ self-report. This research aimed
to develop and establish the content validity of a PRO
measure relevant to patients with moderate to severe
varicose veins that could serve to support a clinical trial
endpoint to assess the efficacy of treatments for the
Table 5 Sociodemographic characteristics of phase 3 cognitive
interview patients
Characteristic N = 29 (100 %)
Age, years







Married or living as married 17 (58.6)
Widowed 2 (6.9)
Separated/divorced 7 (24.1)
Never married 3 (10.3)
Education
High school 11 (37.9)
College 14 (48.3)





Not employed 3 (10.3)
Ethnic group
Hispanic/Latino 2 (6.9)
Not Hispanic/Latino 27 (93.1)
Race
Asian 1 (3.4)
Black or African American 1 (3.4)
White 25 (86.2)
Other 2 (6.9)
How long ago diagnosed with varicose veins (months)
Mean ± standard deviation 157.8 (173.6)
Median 120
Range 1–564
Being treated for varicose veins or related symptoms
No 8 (27.6)
Yes 21 (72.4)
How long have been receiving treatment for varicose veins (in
months)
Mean ± standard deviation 37.0 (99.5)
Median 6.0
Range 1–480




Data are presented as n (%) unless otherwise indicated
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symptoms of superficial venous incompetence of the GSV
system. The VVSymQ instrument was developed based
on qualitative research with patients with varicose veins,
and its development followed FDA guidelines and rec-
ommendations for PRO instruments [5].
Concept elicitation focus groups and individual
interviews indicated that the five HASTITM symptoms
(heaviness, achiness, swelling, throbbing, and itching)
are the most important and relevant symptoms for
patients with varicose veins. These five symptoms
comprising the VVSymQ instrument were imbedded in
an electronic daily diary that was tested in the final
waves of the cognitive interviews. Cognitive testing
indicated that the instructions, items, and response
options were well understood by patients with varicose
veins, the concepts were relevant to patients’ experi-
ences, and patients found the electronic format and
functionality of the device easy to use. The appropriate
population for this instrument is patients with symptoms.
Psychometric results demonstrating the reliability,
validity, and responsiveness of the VVSymQ instru-
ment have been presented [14].
8 Conclusion
Results from this research support the content validity of
the VVSymQ instrument. A combination of focus groups
and individual interviews demonstrated that the five items
of the VVSymQ instrument are the most relevant and
important to patients and appropriately reflect the patient’s
symptom experience. Further, this qualitative work
demonstrated that patients understand and can respond to
the individual VVSymQ items.
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